- WACKER invested over 100 million Euros in expanding its Halle site, creating over 100 jobs.
- The consortium will produce 80 million mRNA vaccine doses annually if needed.
- WACKER will produce plasmid DNA and mRNA active ingredients in Halle, Germany.
- CordenPharma will manufacture lipids and handle aseptic fill & finish in Frankfurt, Chenôve, and Caponago.
Consortium Achieves Pandemic Readiness
WACKER and CordenPharma have officially entered a pandemic readiness state as of 1 June 2024. Following a successful expansion and qualification phase, the companies are now in a stand-by phase for at least five years, prepared to produce 80 million mRNA vaccine doses annually if needed.
Strategic Government Contracts
In response to the initial vaccine shortage during the coronavirus pandemic, the German government awarded pandemic-preparedness contracts to secure future vaccine production and supply. WACKER and CordenPharma, as joint bidders, were among the companies awarded these contracts.
Production Capabilities
WACKER will produce plasmid DNA (pDNA) and mRNA active ingredients at its expanded site in Halle, Germany. The site also includes a new mRNA Competence Center. CordenPharma will manufacture custom and standard lipids at its Frankfurt (DE) and Chenôve (FR) sites, and handle aseptic fill & finish and packaging at its Caponago (IT) facility.
Investment and Expansion
WACKER invested over 100 million Euros in expanding its Halle site, creating over 100 highly qualified jobs. During the two-year qualification phase, CordenPharma invested in new lipid purification capacity, Supercritical Fluid Chromatography (SFC) capabilities, and new compounding and freezing equipment. Both companies have strengthened their production security and supplier network as part of a comprehensive pandemic readiness strategy across their EU sites.
